This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical



Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact





Mist MomentsSafety & Dosing

Safety &



Access & SavingsZavzpret OneSource
Practice Resources

Practice Resources

EventsMaterialsVideosPA Resources
Prescribing InformationPatient Information Instructions for UseIndication Press Release
Access & SavingsAccess & Savings

Retail Pharmacy Fulfillment and Copay Card 

Resources are available to help with affordability and PA.

Copay card
  • Eligible patients with commercial insurance may pay as little as $0 per month*
  • Patients can download and activate a card to get started today by visiting

*Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. The offer will be accepted only at participating pharmacies. This offer is not health insurance. No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For any questions, please call 1-800-761-1568. For full terms and conditions, visit or write to Pfizer Inc. at PO Box 29387, Mission, KS 66201.

Prior AuthorizationTipHave your patient call their pharmacy first to ensure ZAVZPRET is in stock OR consider prescribing ZAVZPRET via Zavzpret OneSource.
Prescribing Explore HCP and patient resources

Including OneSource overview, discussion guides, and more.

See more
What's Zavzpret OneSource?

A personalized support program offering assistance in gaining access to ZAVZPRET.

Learn more

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.


ZAVZPRETTM (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Important Safety Information Contraindications: Hypersensitivity to ZAVZPRET or any of its components.

Warnings and Precautions: Hypersensitivity reactions, including facial swelling and urticaria, have occurred with ZAVZPRET. If a hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy.

Adverse Reactions: Most common adverse reactions (occurring in ≥2% of patients treated with ZAVZPRET and greater than placebo) for ZAVZPRET vs placebo were taste disorders including dysgeusia and ageusia (18% vs 4%), nausea (4% vs 1%), nasal discomfort (3% vs 1%), and vomiting (2% vs 1%).

Drug Interactions: Avoid use with drugs that inhibit or induce OATP1B3 or NTCP transporters. Avoid use of intranasal decongestants; if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.

Use in Specific Populations: Hepatic Impairment: Avoid use in patients with severe hepatic impairment. Renal impairment: Avoid use of ZAVZPRET in patients with creatinine clearance (CLcr) less than 30 mL/min.

Please click here for full Prescribing Information.
IndicationZAVZPRET™️ (zavegepant) is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: ZAVZPRET is not indicated for the preventive treatment of migraine.

Please see Full Prescribing Information.